Endpoint Health Inc
Diego is the CEO of Gemini Therapeutics, developing a safer, next-generation chemotherapy. Diego co-founded GeneWEAVE Biosciences (acquired by Roche) and Endpoint Health. GeneWEAVE developed tests for the rapid detection of bacteria to guide antibiotic treatment. There he invented the core technology, is the author of 27 issued patents, and served as Chief Technology Officer. Endpoint Health was a precision therapeutics company for immune-mediated diseases including Sepsis and ARDS. At Endpoint, Diego served as Chief Scientific Officer and on the company’s Board of Directors. Diego was also the first life sciences Visiting Partner at Y Combinator and is an angel investor. Diego’s training is in Electrical Engineering (BS, UCSB) and Biophysics, Applied Engineering Physics, and Biomedical Engineering (PhD, Cornell University).
Tools for Precision Therapy for Critical Illness (ARDS, Sepsis): Correlating to Treatment Effect
Monday, March 23, 2026
1:50 PM - 2:00 PM Central Time
Disclosure(s): Gemini Therapeutics: Owner/Co-Owner Founder/Co-Founder (Ongoing), Salary (Ongoing)
